Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Date:8/31/2013

duction in recurrent symptomatic VTE among patients with severe pulmonary embolism who were treated with edoxaban."

"We are excited about the results from the Hokusai-VTE study demonstrating that once-daily edoxaban may provide a new treatment option for a broad range of VTE patients. Daiichi Sankyo plans to submit New Drug Applications for edoxaban for VTE by the first quarter of 2014 in the U.S., Japan and Europe," said Glenn Gormley, MD, PhD, Global Head of Research and Development and Senior Executive Officer, Daiichi Sankyo. "Daiichi Sankyo is committed to continuing the global development of edoxaban and looks forward to the presentation of the results from the phase 3 ENGAGE AF-TIMI 48 study in patients with atrial fibrillation at the 2013 American Heart Association Scientific Sessions in November."

About Hokusai-VTE

Hokusai-VTE was a global, event-driven, randomized, double-blind, parallel-group phase 3 clinical study involving 8,292 patients in 439 clinical sites across 37 countries to evaluate once-daily edoxaban in patients with symptomatic DVT and/or PE.1

Patients were randomized to one of two different treatment groups. Both groups received open-label enoxaparin or unfractionated heparin for at least five days, and either warfarin or placebo (administered to edoxaban group), followed by double-blind edoxaban 60 mg (n=4,118) (edoxaban 30 mg for patients with renal impairment or low body weight or p-glycoprotein inhibitor use) or warfarin (n=4,122) for at least three months and up to a maximum of one year (duration of study treatment was determined by the investigator based on the patient's clinical features). Patients were followed for 12 months regardless of treatment duration to provide investigators with a better understanding of outcomes in clinical practice relative to an on-treatment analysis only.1

The primar
'/>"/>

SOURCE Daiichi Sankyo Company, Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
2. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
5. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
6. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
7. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
8. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
9. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
10. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
11. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 According to the ... Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications ... - Global Forecast to 2019" published by MarketsandMarkets, the ... $19,786.3 Million by 2019 from $14,240.0 Million in ... to 2019. Browse 74 market data ...
(Date:9/19/2014)... -- Merck (NYSE: MRK ), known as MSD outside ... , is teaming with celebrity chef and cookbook author Leticia ... an educational program encouraging Hispanics with type 2 diabetes to achieve ... to help reduce the risk of serious health problems. Hispanics in ... risk for developing type 2 diabetes than non-Hispanic white adults, and ...
(Date:9/19/2014)... 2014 Five MinuteClinic walk-in medical clinics are opening inside ... area. Three clinics opened in Memphis and ... will be added in Springfield on September ... is expected to open October 22.  MinuteClinic is the largest and ... United States . The Memphis ...
Breaking Medicine Technology:Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3
... June 4 Mach 7 Technologies (M7T), a global ... global headquarters from suburban Chicago to greater Burlington, ... for Americas, sales and professional service operations, and finance and administration. ... functions. , , , ...
... LAIYANG, China , June 4 /PRNewswire-Asia-FirstCall/ ... company with its principal operations in China , today,announced that the ... Market. , , , ... Jiangbo anticipates that its common stock will begin trading on the ...
Cached Medicine Technology:Mach 7 Technologies Establishes New Headquarters in Burlington, VT 2Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market 2Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market 3
(Date:9/22/2014)... Fancyflyingfox.com, the well-known wedding dress manufacturer and ... plus size wedding dresses . In addition, the company has ... plus size outfits. Each item in the new range is ... off. , The company has thousands of unique special ... available at extremely affordable prices. Its products are brand new ...
(Date:9/21/2014)... of cancer patients who smoke, those using e-cigarettes (in ... equally or less likely to have quit smoking traditional ... , a peer-reviewed journal of the American Cancer Society, ... e-cigarettes for helping cancer patients give up smoking. , ... patients who smoke should be advised to quit. But ...
(Date:9/21/2014)... Phoenix, AZ (PRWEB) September 21, 2014 ... in Phoenix Arizona announces record demand for aggressively discounted ... of accidents occurring throughout the Valley each year, it ... to have access to discounted attorney’s fees as a ... said, Hastings and Hastings has been a frontrunner when ...
(Date:9/21/2014)... peanuts are more likely to trigger an allergy to ... involving mice. , The researchers say that specific chemical ... roasting process are recognised by the body,s immune system, ... response the next time it sees any peanuts. , ... of people with peanut allergies in the Western world ...
(Date:9/21/2014)... New York (PRWEB) September 21, 2014 ... of their Risk Management Portal designed for Diocesan ... with the intent to support effective risk management ... scheduled to go live coinciding with Waldorf’s exhibition ... 21-24, 2014. , These applications were developed in ...
Breaking Medicine News(10 mins):Health News:Discounted Plus Size Wedding Dresses Available At Fancyflyingfox.com 2Health News:E-cigarettes unhelpful in smoking cessation among cancer patients 2Health News:Hastings & Hastings Announces Record Demand For Aggressively Discounted Accident Victim Attorney’s Fees 2Health News:Hastings & Hastings Announces Record Demand For Aggressively Discounted Accident Victim Attorney’s Fees 3Health News:Dry roasting could help trigger peanut allergy 2Health News:Waldorf Risk Solutions Releases New Risk Management Portal 2
... enough alcohol to become intoxicated increases aggression significantly in people ... But people without that trait don,t get any more ... That trait is the ability to consider the future consequences ... and now, without thinking about the impact on the future, ...
... , MONDAY, Dec. 19 (HealthDay News) -- Most parents who ... the safety of the toys they buy, asking about toxins ... buyer/manager, Kathie Dockstader, said. "They want to know about ... strong toy safety laws in effect now," Dockstader said. "Each ...
... Children may have a better quality of life (QOL) ... 1 (ET-1) levels after adenotonsillectomy, according to new research ... Head and Neck Surgery . SDB ... due to obstructive sleep apnea syndrome (OSAS). Cardiovascular (CV) ...
... MD December 19, 2011 The University of ... to secure research opportunities to advance the science of ... grants awarded to the Department by the National Institutes ... strongly on the qualitative excellence of the University of ...
... By Amanda Gardner HealthDay Reporter , FRIDAY, Dec. ... cancer who receive targeted radiation to the breast after a ... However, only about a third of these women were considered ... new study published in the Dec. 16 online issue of ...
... clinical trials have highlighted the beneficial effect of ... symptoms and reduction of mortality, and CRT is ... guidelines for the treatment and prevention of heart ... selected subjects and their results are not always ...
Cached Medicine News:Health News:1 trait has huge impact on whether alcohol makes you aggressive 2Health News:1 trait has huge impact on whether alcohol makes you aggressive 3Health News:Choosing a Toy? Think 'Kid-Powered' 2Health News:Effect of adenotonsillectomy in children with sleep-disordered breathing 2Health News:University of Maryland Department of surgery continues to lead through surgical innovation 2Health News:University of Maryland Department of surgery continues to lead through surgical innovation 3Health News:Targeted Radiation for Breast Cancer May Be Overused: Study 2Health News:Targeted Radiation for Breast Cancer May Be Overused: Study 3Health News:The benefits of cardiac resynchronisation therapy in heart failure 2Health News:The benefits of cardiac resynchronisation therapy in heart failure 3
... in Stability. The ... features superior arm strength ... the clamp/turret mechanism. ... the ultimate flexibility incorporated ...
Part of the Octopus System which includes both the Starfish & Octopus3. The Octopus3 Tissue Stabilizer is the pioneering and market-leading suction device....
... Guidant's fourth generation access device - XPOSE ... the heart. The XPOSE 4 Device is ... off-pump bypass surgery and to easily position ... Designed for both apical and non-apical placement ...
... Since its U.S. approval in 1992, ABIOMED's BVS ... used advanced cardiac assist system in the world ... device approved by the U.S. Food and Drug ... failure. ABIOMED continues to make advances with ...
Medicine Products: